

## Double, Triple and Quadruple Treatment Strategies for COVID-19

**Behzad Saberi\***

*Medical Research, Esfahan, Iran*

**\*Corresponding Author:** Behzad Saberi, Medical Research, Esfahan, Iran.

**Received:** May 01, 2020; **Published:** June 26, 2020

There are some recommendations for the Novel Coronavirus treatment. This is a brief review on double, triple and quadruple treatment strategies for the affected patients.

Based on the physical examination and the acquired test results from the patients, the treatment strategies can be selected. There are suspicious, probable and definite cases.

Combination of Oseltamivir and Chloroquine phosphate or Hydroxy Chloroquine sulfate is the foundation for double treatment strategy which is mainly used in outpatient settings.

Triple and quadruple treatment strategies are employed in the inpatient settings.

Combination of Oseltamivir, Chloroquine phosphate or Hydroxy Chloroquine sulfate and Lopinavir/Ritonavir (Kaletra) makes the triple treatment strategy. In case the patients have any of these signs including Pulmonary multi lobular infiltration, Decreased level of consciousness, Hypoxemia, increased respiratory rate and Decreased blood pressure which demonstrate the more severe settings, quadruple treatment strategy can be employed. Quadruple treatment strategy would be a combination of triple treatment strategy with Ribavirin.

During employing double treatment strategy, Chloroquine phosphate or Hydroxy Chloroquine sulfate would be administered for five days but during triple and quadruple treatment strategies employment, any of these medications will be administered just one time as a single dose. Other medications including Oseltamivir, Lopinavir/Ritonavir (Kaletra) and Ribavirin will be administered for five days or more based on the clinical responses of the individual patients to treatment.

It is important for the health care professionals who deal with the patients with Novel Coronavirus, to have enough knowledge about the available and updated treatment strategies [1-6].

### Bibliography

1. Gao J., *et al.* "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies". *BioScience Trends* 14.1 (2020): 72-73.
2. Jin Y., *et al.* "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)". *Military Medical Research* 7.1 (2020): 4.
3. World Health Organization. "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected".

4. Peiris JSM., *et al.* "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study". *Lancet* 361.9371 (2003): 1767-1772.
5. Huang C., *et al.* "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". *Lancet* 395.10223 (2020): 497-506.
6. Chu CM., *et al.* "Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings". *Thorax* 59.3 (2004): 252-256.

**Volume 11 Issue 7 July 2020**

**©All rights reserved by Behzad Saberi.**